Myriad Teams with Topin to Market OnDose to Oncologists | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.

Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.